Related Experiment Video

Updated: May 25, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Skp2 is a promising therapeutic target in breast cancer

Zhiwei Wang1, Hidefumi Fukushima, Hiroyuki Inuzuka

  • 1Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Frontiers in Oncology
|January 27, 2012
PubMed

Insights

S-phase kinase associated protein 2 (Skp2) is crucial in breast cancer development. This review highlights Skp2 functions and explores natural compounds as potential Skp2 inhibitors for breast cancer prevention and treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Breast cancer is a leading cause of death for women in the US.
  • Key factors in breast cancer include estrogen receptor, Notch, PTEN, HER2, PI3K/Akt, BRCA1, and BRCA2.
  • Emerging research implicates the F-box protein Skp2 in breast cancer pathogenesis.

Purpose of the Study:

  • To review the novel functions of Skp2 in breast cancer.
  • To explore Skp2 inhibitors, particularly natural chemopreventive agents, for targeted breast cancer therapy.

Main Methods:

  • Literature review of Skp2's role in breast cancer.
  • Analysis of existing data on Skp2 functions and inhibitors.
  • Synthesis of information on natural compounds with potential Skp2 inhibitory activity.

Main Results:

  • Skp2 plays a significant role in the development and progression of breast cancer.
  • Several signaling pathways are implicated in breast cancer, with Skp2 emerging as a key player.
  • Natural compounds show promise as targeted agents for Skp2 inhibition.

Conclusions:

  • Skp2 is a critical factor in breast cancer pathogenesis.
  • Targeting Skp2 offers a novel therapeutic strategy for breast cancer.
  • Natural chemopreventive agents represent a promising avenue for Skp2-targeted breast cancer prevention and treatment.

More Related Videos

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors08:45

Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors

Published on: July 17, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...